WO2004035754A3 - Microencapsulation and sustained release of biologically active polypeptides - Google Patents

Microencapsulation and sustained release of biologically active polypeptides Download PDF

Info

Publication number
WO2004035754A3
WO2004035754A3 PCT/US2003/033062 US0333062W WO2004035754A3 WO 2004035754 A3 WO2004035754 A3 WO 2004035754A3 US 0333062 W US0333062 W US 0333062W WO 2004035754 A3 WO2004035754 A3 WO 2004035754A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
sustained release
active polypeptides
microencapsulation
compositions
Prior art date
Application number
PCT/US2003/033062
Other languages
French (fr)
Other versions
WO2004035754A2 (en
Inventor
Henry R Costantino
Joyce Hotz
Original Assignee
Alkermes Inc
Henry R Costantino
Joyce Hotz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc, Henry R Costantino, Joyce Hotz filed Critical Alkermes Inc
Priority to AU2003286472A priority Critical patent/AU2003286472A1/en
Publication of WO2004035754A2 publication Critical patent/WO2004035754A2/en
Publication of WO2004035754A3 publication Critical patent/WO2004035754A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide, a sugar and a salting-out salt.
PCT/US2003/033062 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides WO2004035754A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003286472A AU2003286472A1 (en) 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41938802P 2002-10-17 2002-10-17
US60/419,388 2002-10-17

Publications (2)

Publication Number Publication Date
WO2004035754A2 WO2004035754A2 (en) 2004-04-29
WO2004035754A3 true WO2004035754A3 (en) 2004-10-07

Family

ID=32108072

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/033198 WO2004035762A2 (en) 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides
PCT/US2003/033168 WO2004036186A2 (en) 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides
PCT/US2003/033062 WO2004035754A2 (en) 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2003/033198 WO2004035762A2 (en) 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides
PCT/US2003/033168 WO2004036186A2 (en) 2002-10-17 2003-10-17 Microencapsulation and sustained release of biologically active polypeptides

Country Status (3)

Country Link
US (4) US7462365B2 (en)
AU (3) AU2003282955A1 (en)
WO (3) WO2004035762A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2004035762A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
AU2003284028B2 (en) * 2002-10-17 2007-05-10 Alkermes, Inc. Sustained release profile modification
ES2600554T3 (en) * 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevention of polymer molecular weight reduction, impurity formation and gelation in polymeric compositions
US20060057180A1 (en) * 2004-02-20 2006-03-16 Ashutosh Chilkoti Tunable nonfouling surface of oligoethylene glycol
CN1968700A (en) * 2004-04-15 2007-05-23 阿尔克姆斯有限公司 Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005113784A1 (en) 2004-05-12 2005-12-01 Luca Technologies, Llc Generation of hydrogen from hydrocarbon-bearing materials
NZ553149A (en) * 2004-08-12 2010-01-29 Quest Pharmaceutical Services Use of inositol hexaphosphate or inositol hexasulphate to complex biologically active compounds for the preparation of controlled release pharmaceutical compositions
US7597907B2 (en) * 2004-11-05 2009-10-06 Trustees Of The University Of Pennsylvania Antioxidant polymer nanocarriers for use in preventing oxidative injury
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006110887A2 (en) * 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
RU2412199C2 (en) * 2005-04-18 2011-02-20 Ново Нордиск А/С Versions of il-21
CA2611200A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised il-21 compositions
CN100429227C (en) 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin 4 polypeptide segment
EP2347762B1 (en) 2005-08-19 2019-05-08 Amylin Pharmaceuticals, LLC Exendin for treating diabetes and reducing body weight
KR20080043301A (en) * 2005-09-14 2008-05-16 아레스 트레이딩 에스.에이. Method for the quantitative determination of poloxamers
ES2586236T3 (en) * 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedures for administering hypoglycemic agents
WO2007081321A1 (en) * 2006-01-09 2007-07-19 Alkermes, Inc. Ac2993 lar dosing regimen
US7416879B2 (en) 2006-01-11 2008-08-26 Luca Technologies, Inc. Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content
US7696132B2 (en) 2006-04-05 2010-04-13 Luca Technologies, Inc. Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material
US7977282B2 (en) 2006-04-05 2011-07-12 Luca Technologies, Inc. Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material
JP2009535380A (en) * 2006-05-02 2009-10-01 アクトジェニックス・エヌブイ Microbial intestinal delivery of obesity-related peptides
KR20140109509A (en) * 2006-07-11 2014-09-15 큐피에스 엘엘씨 Pharmaceutical compositions for sustained release delivery of peptides
KR101200728B1 (en) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 Osmotic delivery system and piston assemblies
CN101553501A (en) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 IL-21 variants
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
EP2109620B1 (en) * 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
KR100805208B1 (en) * 2007-03-27 2008-02-21 주식회사 펩트론 Composition and microsphere for controlled-release of exendin and method of preparing the same
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
US8568786B2 (en) * 2007-10-27 2013-10-29 The Trustees Of The Universtiy Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
US7927629B2 (en) * 2007-10-27 2011-04-19 The Trustees Of The University Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
FI2341905T4 (en) 2008-09-04 2023-12-04 Amylin Pharmaceuticals Llc Sustained release formulations using non-aqueous carriers
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
JP5892940B2 (en) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム Mucosal delivery composition comprising a peptide complexed with a crown compound and / or counterion
BRPI1003424A2 (en) * 2010-09-08 2013-01-08 Univ Rio De Janeiro human amylin containment polymeric system and agonist analogs, process and use; functional assessment process of released amylin
EP2654658A4 (en) * 2010-12-23 2016-04-06 Tailorpill Technologies Llc System and methods for personalized pill compounding
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140220134A1 (en) * 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
CN102488619B (en) * 2011-12-05 2014-08-06 上海交通大学 Device for continuously producing exenatide microspheres and method for controlling release rate of microspheres
US20150258198A1 (en) 2012-08-14 2015-09-17 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
WO2014027253A1 (en) 2012-08-14 2014-02-20 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
CN104840415B (en) 2014-02-19 2019-03-15 香港浸会大学 Long-acting controlled release lipidosome gel composition containing blood-sugar decreasing active and preparation method thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10537373B2 (en) * 2015-04-24 2020-01-21 Biomet Sports Medicine, Llc Porous implants with injectable capabilities
KR20240042548A (en) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
MA53353A (en) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28733A (en) * 1860-06-19 Game-box
BE634668A (en) 1962-07-11
BE744162A (en) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd ENCAPSULATION PROCESS
DE2010115A1 (en) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
JPS523342B2 (en) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
KR920702383A (en) * 1989-08-28 1992-09-03 원본미기재 Biocorrosive polymers useful for controlling the release of therapeutic agents
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1994005265A1 (en) 1992-09-10 1994-03-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
JP3698721B2 (en) 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド Excipient stabilization of polypeptides treated with organic solvents
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
AU677115B2 (en) 1994-12-19 1997-04-10 University Of Miami Biodegradable injectable drug delivery polymer
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
DE69717263T2 (en) 1996-03-28 2003-07-24 Takeda Chemical Industries Ltd PREPARATION WITH DELAYED RELEASE AND THEIR PRODUCTION
CN1126537C (en) 1996-05-23 2003-11-05 株式会社三养社 Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
WO1997046584A1 (en) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin analogues, processes for their preparation and medicaments containing them
US6956026B2 (en) * 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
AU5696198A (en) 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
MXPA03005135A (en) * 2000-12-13 2003-12-04 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides.
NZ535008A (en) 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles

Also Published As

Publication number Publication date
US8129339B2 (en) 2012-03-06
WO2004036186A3 (en) 2004-12-23
US7462365B2 (en) 2008-12-09
AU2003282955A1 (en) 2004-05-04
AU2003277446A1 (en) 2004-05-04
WO2004035754A2 (en) 2004-04-29
AU2003282955A8 (en) 2004-05-04
US20040228833A1 (en) 2004-11-18
AU2003286472A8 (en) 2004-05-04
AU2003277446A8 (en) 2004-05-04
US7164005B2 (en) 2007-01-16
US20040208929A1 (en) 2004-10-21
AU2003286472A1 (en) 2004-05-04
US20070027085A1 (en) 2007-02-01
WO2004035762A3 (en) 2004-08-05
WO2004036186A2 (en) 2004-04-29
WO2004035762A2 (en) 2004-04-29
US20090281034A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
WO2004035754A3 (en) Microencapsulation and sustained release of biologically active polypeptides
LU91989I9 (en)
WO2001044239A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2005045001A3 (en) Insulin-producing cells derived from stem cells
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
NO20065213L (en) Poly (lactide-co-glycolide) -based sustained-release microcapsules comprising a polypeptide and a sugar
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2006071840A8 (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2004039948A3 (en) Actriib fusion polypeptides and uses therefor
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
WO2006023665A3 (en) Il-1 antagonist formulations
AU2003252299A1 (en) Novel physiologically active substance
WO2007087053A3 (en) Bmp-7 variant compositions, methods and uses
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
AU2003281358A1 (en) Pin1 peptidyl-prolyl isomerase polypeptides, their crystal structures, and use thereof for drug design
AU2003215708A1 (en) Orodispersible pharmaceutical composition comprising perindopril
WO2002062856A3 (en) Microencapsulated biologically active substances that contain a water-soluble or water-dispersible comb polymer
AU2003219569A1 (en) Antimicrobial peptide, its analogs and antimicrobial composition comprising them
WO2003006492A3 (en) Biologically active peptides
AU2003269871A1 (en) Radiosensitizer composition containing n-acetylphytosphingosine analogs and n,n-dimethyl-phytosphingosine analogs as the active ingredients
MY138799A (en) Orodispersible pharmaceutical composition of an antithrombotic compound
EP1571148A4 (en) 3-phenyl-cinnoline homologue and antitumor agent containing the same
WO2002066513A3 (en) Human circulating lekti fragments hf7072, hf7638 and hf14448 and use thereof
WO2003048206A3 (en) Growth hormone agonist peptides and their uses
AU2003226712A1 (en) Protein kinase c modulators, their aminoacid and nucleotide sequences and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP